Navigation Links
Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results

EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced its financial results for the quarter ended September 30, 2008, the first quarter of the company's fiscal year ending June 30, 2009. Revenue for the three months ended September 30, 2008 was $3.6 million, compared to $3.9 million for the three months ended September 30, 2007. Operating expenses were $6.8 million for the first quarter of fiscal 2009 compared to $7.1 million for the same period in the prior year. Within the company's operating expenses, research and development was $5.5 million for each of the first quarters of fiscal 2009 and 2008, and general and administrative decreased to $1.3 million for the first quarter of fiscal 2009 compared to $1.7 million for the first quarter of fiscal 2008. The company's operating loss was $3.2 million for both periods. Net loss was $2.8 million for the three months ended September 30, 2008 compared to $0.9 million for the three months ended September 30, 2007. The increased net loss for the fiscal 2009 quarter was primarily due to a non-cash gain of $2.9 million recorded in the fiscal 2008 period as a result of fair-value accounting for a financial instrument. Net loss per share was $0.10 for the three months ended September 30, 2008 compared to $0.19 for the three months ended September 30, 2007. As of September 30, 2008, the company had $28.2 million in cash and short-term investments. The company also held $10.3 million in auction rate securities, which are classified as long-term investments.

"Our clinical team is making important progress on the development of Viprinex(TM) for acute ischemic stroke as we start our new fiscal year. This dedicated group is preparing for the upcoming interim analysis while simultaneously accelerating trial enrollment for the subsequent final analysis of this pivotal trial," said Paul E. Freiman, president and chief executive officer. "The Viprinex studies have recently surpassed a total of 600 patients enrolled (out of a target of 650 patients), the first 500 of which will be considered for the upcoming interim analysis, which we expect to complete by January 2009. The interim futility review will constitute a major go/no-go decision for the Viprinex program, since it is the first efficacy assessment ever by our independent Data Safety Monitoring Board (DSMB). For the trial to pass futility, Viprinex must demonstrate predetermined efficacy criteria. If we pass the interim evaluation, the clinical data will remain blinded until the final analysis of the trial, which we expect to complete by mid-2009."

NTI also announced that it has amended its stockholder rights plan, originally adopted by the Board of Directors in 2005, to increase the percentage of the company's common stock that can be acquired by a shareholder from 15 to 20% before rights are triggered under the plan.

Conference Call Information

NTI will webcast its quarterly financial results and host a conference call today at 10:30 a.m. (ET), 7:30 a.m. (PT). Dial-in number (800) 309-1245 (U.S. and Canada) and 719-457-2080 (International). The webcast can be accessed by going to . A playback of the conference call will be available from 1:30 p.m. (ET) today through midnight (ET) on November 13, 2008. Replay number: (888) 203-1112 (U.S. and Canada) / (719) 457-0820 (international). Replay access code: 8094663.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the development of Viprinex for acute ischemic stroke, delays or other problems with our clinical trials, the outcome of the interim analysis, the time and costs for obtaining approval for Viprinex, and levels of future expenditures and capital resources needed to fund operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, as updated periodically in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.




(in thousands, except per share data)

Three months ended

September 30,

2008 2007


Royalty $2,078 $1,981

Technology sale and collaboration services 1,487 1,919

Total revenues 3,565 3,900


Research and development 5,452 5,460

General and administrative 1,331 1,659

Total expenses 6,783 7,119

Operating loss (3,218) (3,219)

Interest income 249 28

Gain on sale of long-term investments 170 --

Interest expense, including non-cash

amortization of $588 discount on

notes for the three months ended

September 30, 2007 -- (633)

Non-cash gain on decrease in fair

value of warrants 37 2,902

NET LOSS $(2,762) $(922)


Shares used in basic and diluted net loss

per share calculation 26,924 4,772


(in thousands)

September 30, June 30,

2008 2008

Unaudited Note 1

Cash and cash equivalents $26,122 $27,941

Short-term investments 2,059 2,039

Long-term investments 10,274 11,850

Total assets 39,338 43,187

Current liabilities 10,067 9,042

Total liabilities 22,101 22,901

Stockholders' equity 17,237 20,286

Note 1: Information as of June 30, 2008 has been derived from the audited financial statements at that date.

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
2. Neurobiological Technologies Sets Date for First Quarter Financial Results
3. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
5. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
6. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
7. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
8. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
9. Neurobiological Technologies CEO to Retire on December 31, 2008
10. Neurobiological Technologies Reports Third Quarter Financial Results
11. Neurobiological Technologies Sets Date for Third Quarter Financial Results
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today announced ... Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology ...
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
(Date:11/24/2015)... --> --> ... Synthesis Market by Product & Services (Primer, Probe, Custom ... RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - ... is expected to reach USD 1,918.6 Million by 2020 ... of 10.1% during the forecast period. Browse ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... JOSE, Calif. , Oct. 27, 2015 Synaptics ... interface solutions, today announced that Google has adopted the ... of touch controller solutions to power its newest flagship ... 6P by Huawei. --> ... partners like Google to provide strategic collaboration in the ...
(Date:10/23/2015)... GOLETA, California , October 23, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) announce a mobile plug and play ... during interactive real-world tasks SensoMotoric Instruments (SMI) ... their established wearable solutions for eye tracking and physiological ... captured with SMI Eye Tracking Glasses 2w ...
Breaking Biology News(10 mins):